Trial Profile
Multiple ascending-dose study of ICA 105665 at doses of up to 600mg in healthy volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Mar 2011
Price :
$35
*
At a glance
- Drugs ICA 105665 (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors Neusentis
- 07 Mar 2011 Status changed from planning to completed.
- 05 May 2010 New trial record